Acute Heart Failure (AHF) Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Robust Pipeline of Drugs
   3. Market Restraints
      1. Stringent Regulatory Requirements
      2. High Research and Development Costs
   4. Market Opportunities
      1. Rising Integration of Digital Health Technologies and Telemedicine Solutions
   5. Market Trends
      1. Personalized Medicine
      2. Integration of Digital Health
5. MARKET SEGMENTATION
   1. By Disorder Type
   15. Right-sided Heart Failure
   15. Left-sided Heart Failure
       • Systolic Failure
       • Diastolic Failure
   16. Congestive Heart Failure
   2. By Drug Category
      1. Angiotensin-Converting Enzyme (ACE) Inhibitors
         1. Captopril (Capoten)
         2. Enalapril (Vasotec)
         3. Fosinopril (Monopril)
         4. Lisinopril (Prinivil, Zestril)
         5. Perindopril (Aceon)
         6. Quinapril (Accupril)
         7. Ramipril (Altace)
         8. Others
      2. Angiotensin II Receptor Blockers
         1. Candesartan (Atacand)
         2. Losartan (Cozaar)
         3. Valsartan (Diovan)
      3. Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
         1. Sacubitril/valsartan
      4. If Channel Blocker
         1. Ivabradine (Corlanor)
      5. Beta Blockers
         1. Bisoprolol (Zebeta)
         2. Metoprolol Succinate (Toprol XL)
         3. Carvedilol (Coreg)
         4. Others
      6. Aldosterone Antagonists
         1. Spironolactone (Aldactone)
         2. Eplerenone (Inspra)
         3. Diuretics
         4. Furosemide (Lasix)
         5. Bumetanide (Bumex)
         6. Torsemide (Demadex)
         7. Chlorothiazide (Diuril)
      7. Amiloride (Midamor Chlorthalidone (Hygroton)
         1. Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril)
         2. Others
      8. Anticoagulants (Blood Thinners)
         1. Cholesterol Lowering Drugs (Statins)
         2. Digoxin
   3. By Distribution Channel:
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amgen Inc.
      2. Bayer AG
      3. Bristol-Myers Squibb Company
      4. Cardiorentis AG
      5. Cytokinetics, Inc.
      6. Merck & Company, Inc.
      7. Novartis AG
      8. Ono Pharmaceutical Co., Ltd.
      9. Pfizer Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Acute Heart Failure (AHF)market?

The global market of Acute Heart Failure (AHF) is projected to reach USD 2622.8 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Acute Heart Failure (AHF)market?

The global Acute Heart Failure (AHF) market has an estimated annual growth rate of 25.5% .

Q.3. What are the recent trends of Acute Heart Failure (AHF)market?

Personalized medicine and integration of digital healthare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Acute Heart Failure (AHF)?

The major companies profiled in this report include Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Cardiorentis AG, Cytokinetics, Inc., Merck & Company, Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Pfizer Inc., among others.

Q.5. Which region is estimated to held highest CAGR inAcute Heart Failure (AHF)market?

North America is estimated to hold biggest share in the market for Acute Heart Failure (AHF).